Schedule III Reclassification Unlocks Tax Relief for AdvisorShares Global Cannabis ETF
Reclassification of cannabis to Schedule III removes a major barrier and unlocks research, capital, and institutional participation for AdvisorShares’ cannabis ETFs including its global cannabis ETF. Legal shift offers relief from punitive tax treatment and could boost YOLO fund flows and normalize valuations for more than 400,000 industry workers.
1. Federal Rescheduling to Schedule III
Federal reclassification of cannabis to Schedule III under the Controlled Substances Act moves the industry out of a policy gray area and into a regulated framework. This shift removes Schedule I restrictions that have hindered research, banking, and capital markets participation.
2. Impact on AdvisorShares Cannabis ETFs
The change directly benefits AdvisorShares’ actively managed cannabis ETFs, including the global cannabis ETF and its U.S.-focused Pure US Cannabis ETF. Managers expect improved fund flows and greater institutional allocations driven by reduced federal uncertainty.
3. Tax Treatment and Research Access
Schedule III status enables relief from punitive tax rules such as Section 280E, potentially improving after-tax earnings for companies in the ETF portfolios. It also opens the door for expanded clinical and agricultural research, strengthening fundamentals over the long term.
4. Industry Outlook and Remaining Barriers
More than 400,000 industry employees stand to gain from improved banking access and clearer oversight, but state-level regulations and licensing hurdles persist. Market participants view this as just the beginning of broader reform to normalize cannabis as a mainstream U.S. industry.